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Purpose: To investigate the efficacy, safety, and mechanisms of Sirolimus sustained delivery film on prevention of scar
formation in a rabbit model of glaucoma filtration surgery.
Methods: Sixty-four New Zealand white rabbits who underwent trabeculectomy in the right eye were randomly allocated
to one of the four treatment regimens: Sirolimus sustained delivery film treatment group (Group A), or drug-free film
treatment group (Group B), or 30 ng/ml Sirolimus-soaked sponge treatment group (Group C), or no adjunctive treatment
group (Group D), and each group consists of 16 rabbits. Intraocular pressure (IOP), morphologic changes of bleb, anterior
chamber flare, and corneal endothelial cell count and complications were evaluated over a 28-day period follow-up time.
Aqueous humor samples were gathered from Group A, and the concentration of Sirolimus was measured regularly post-
operation. Rabbits were sacrificed on the 7th, 14th, and 28th day post-operation separately, and the fibroblast hypertrophy,
infiltration of inflammatory, and proliferation of new collagen fiber formation in each group were evaluated with HE and
Masson  staining.  Proliferative  cell  nuclear  antigen  (PCNA)  and  fibroblast  apoptosis  were  evaluated  by
immunohistochemistry and terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) assay at
the 28th day post-operation.
Results: Both Sirolimus sustained delivery film (Group A) and Sirolimus alone (Group C) were well tolerated in this
model, and significantly prolonged bleb survival compared with no drug treatment group (Group B and D; p<0.001).
Group A had the longest bleb survival time in comparison with other groups (p<0.001). There were significant differences
in IOP readings between Group A and other groups at the last follow-up (p<0.05). The concentration of Group A
maintained stable for over 2 weeks, drops from (10.56 ±0.05) ng/ml at day 3 to (7.74 ±0.05) ng/ml at day 14. The number
of corneal endothelial cells of Group A was not statistically significant between pre and post-operation. Histologic
examination demonstrated that eyes treated with Sirolimus, especially the Sirolimus sustained delivery film, showed an
obvious reduction in subconjunctival fibroblast scar tissue formation compared with no drug treatment groups, and had
minimal  evidence  of  inflammatory  cell  infiltration  and  new  collagen  deposition  in  the  subconjunctiva.
Immunohistochemistry assay showed that PCNA-expression was lower in the Group A (16.25±3.24%) compared to other
groups (p<0.01). TUNEL assay showed a significant increase in the number of apoptotic fibroblasts around the surgical
area in Group A and Group C (9.75±1.71% and 8.50±1.92%) compared to the Group B and D (p<0.01).
Conclusions: Sirolimus drug sustained delivery film can inhibit inflammatory cell activity, impede fibroblast proliferation
activity, and induce fibroblast apoptosis in the filtration surgery sites in rabbit. The results indicate a safe and effective
treatment strategy in anti-scaring treatment in glaucoma surgery.
Filtration surgery is currently one of the most effective
methods to treat glaucoma. The most prevalent reason of
failures in filtration surgery is post-operation scarring of the
filtration path [1]. Due to overhealing of subconjuctiva at the
bleb and sclerostomy sites, the failure rate of this surgery can
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reach  15%–30%  [1,2].  Despite  numerous  anti-metabolites
medications (e.g., Mitomycin C [MMC] and 5-Fluorouracil
[5-FU])  greatly  increased  the  success  rate  of  glaucoma
surgeries.  However,  these  drugs  may  lead  to  increased
incidences of complications, such as persistent postoperative
hypotony, corneal problems, filtering bleb leakage, etc [3-6].
Therefore, developing a low toxicity, safe, effective and long
lasting  medication  for  anti-proliferation  after  filtration
surgery  has  long  been  an  important  area  of  research  for
glaucoma.
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2495Sirolimus,  also  known  as  Rapamycin  (RAPA),  is  a
natural  product  isolated  from  Streptomyces  hygroscopicus
[7]. It is a macrolide currently used as an immunomodulatory
medication,  an  anti-tumor  agent,  or  an  anti-viral  agent,
featuring low toxicity and high efficiency [7-10]. Researches
have indicated that Siromilus has a strong inhibition effect on
the  fibroblasts  from  the  Tenon’s  capsule  through  inhibit
platelet-derived  growth  factor-induced  fibroblast
proliferation in vitro without any apparent cytotoxicity [11].
Thus it is possible for it to become an ideal anti-proliferation
medication for glaucoma filtration surgery.
Until recently, the anti-metabolite medication was used
transiently on the surgery site with a sponge soaked with
special drug (MMC or 5-FU, etc) [3,4]. The application time
and the concentration of these drugs had no identical criteria.
Thus, the sustained drug delivery system (DDS) with constant
effective concentration would be a useful way to get better
clinical outcomes.
The purpose of this study is to investigate the effects of
a Sirolimus sustained delivery film on the conjunctiva and
scleral wound healing process after filtration surgery in rabbit
eyes.  We  found  this  delivery  system  may  be  a  safe  and
effective treatment to inhibit inflammatory cell activity and
fibroblast  activity  in  surgery  sites,  and  can  significantly
improve outcome of filtration surgery.
METHODS
Creation of the Siromilus sustained-delivery film: The drug
delivery film was developed by the School of Pharmaceutical
Science, Sun Yat-sen University (Guangzhou, Guangdong
Province,  P.R.  China),  and  its  production  process  is  as
follows:  (1)  Accurate  weigh  PEG4000  36  mg  in  5  ml
centrifuge  tube,  add  1.5  ml  dichloromethane,  vortex  to
dissolve. (2) Weigh polymer polyactioglyconic acid (PLGA,
Durect  Corporation,  Birmingham,  UK;  inherent  viscosity
0.55–0.75 dl/g, degeneration time: 8–12 weeks) 42 mg, PLGA
(inherent viscosity 0.17 dl/g, degeneration time: 2–4 weeks)
15.6  mg,  Siromilus  (Hangzhou  sino-us  east  China
pharmaceutical Co., LTD, Hangzhou, China) 14 mg in 2 ml
centrifuge tube, add 600 μl of the solution from (1), vortex 10
min to dissolve, set aside for 5 min. After the Siromilus was
dissolved, the solution was dropped onto a slide in a ventilated
hood  until  the  solvent  evaporates,  and  then  the  film  was
collected.  Before  application  in  the  surgery,  the  film
underwent ethylene oxide fumigation for 24 h in the dark.
Animals  and  anesthesia:  All  animal  experiments  were
conducted according to the guidelines of the ARVO Statement
for the Use of Animals in Ophthalmic and approved by the
Ethics Committee of Zhongshan Ophthalmic Center, Sun Yat-
sen University.
New Zealand white female rabbits (weight, 2–2.8 kg; age,
10–12  weeks)  were  purchased  from  Guangdong  Medical
Laboratory Animal Center. Rabbits were anesthetized with an
intramuscular injection of ketamine hydrochloride (50 mg/kg)
and  chlorpromazine  hydrochloride  (10  mg/kg)  before
surgeries  and  examinations.  The  right  eye  (OD)  of  each
animal was used as experimental eye, and the contralateral left
eye (OS) was considered as control. Sixty-four healthy rabbits
were randomly divided into 4 groups (16 per group), and
described  as  follow.  (1)  Group  A:  Sirolimus  sustained
delivery film implanted under conjuctiva; (2) Group B: Drug-
free film implanted; (3) Group C: Sponge with a concentration
of 30 ng/ml Sirolimus applied to the surgery site for 3 min and
then wash out with Balance Saline Solution (BSS); (4) Group
D:  Trabeculectomy  without  adjunctive  treatment.  All
investigations  involving  rabbits,  including  IOP
measurements, slit lamp examination, corneal endothelial cell
count,  and  determination  of  histologic  features,  were
conducted in a blind manner by two experienced researchers.
Filtration  surgery  protocol:  After  topical  anesthesia  with
0.5%  tetracaine  eye  drops,  a  limbus-based  flap  of  the
conjunctiva and the Tenon’s capsule was made at a distance
of 5 mm from the limbus in the superior quadrant of the right
eye. After that, a half-thickness, rectangular, 4×3 mm scleral
flap was created. A 2×1.5 mm scleroectomy was followed by
Figure 1. Sustained delivery film application during filtering surgery.
A drug delivery film in white sheet form, approximately 2.5 mm×2.5
mm  in  size  (arrow),  placed  in  the  surgical  area  between  the
conjunctiva flap and scleral flap.
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2496peripheral iridoectomy. The scleral flap was closed with 10–
0 nylon sutures. The conjunctiva was closed with a continuous
locking suture with 8–0 Vicryl thread (Johnson & Johnson,
Ethicon,  NJ).  Before  suturing  the  conjunctiva  flap,  the
Sirolimus sustained delivery film and blank film with the size
of 2.5×2.5 mm were sutured onto the scleral which above the
flap with 10–0 nylon thread at two cross corners in Group A
and Group B, respectively (Figure 1). In Group C, cotton pad
of size 4×3 mm with Siromilus concentrate of 30 ng/ml was
applied between the scleral flap and conjunctiva flap for 3 min,
and then rinsed with 200 ml BSS. In Group D, no adjunctive
treatment was applied, and only treated with trabeculectomy.
After the surgery, treatment of TobraDex eyeointment
was applied to the conjunctival sac. Post-operative treatment
included tobramycin eyedrops (4 times daily), and tobramycin
eyeointment (once per day) for a week. All operations and
treatments  were  implemented  by  experienced
ophthalmologists (R.J.L. and Y.H.Z.).
Preoperative and postoperative examinations:
Intraocular  pressure  (IOP)—Tono-Pen  AVIA
applanation tonometer was used to measure IOP during pre-
op, post-op days 1, 3, 5, 7, 10, 14, 21, and 28 according to the
manufacture procedure. Briefly, 0.5% tetracaine eye drops
were  applied  on  the  tested  eyes  2–3  times  before
measurements. After the rabbit’s head is stabilized, the tip of
the measuring head was gently touch perpendicular onto the
central  corneal  zone  until  results  were  shown,  then  were
subsequently recorded (with ≥95% confidence interval). Each
eye was measured 3 times, and the average value was taken.
Slit lamp examination—A slit lamp microscope was
used to observe the eyes during post-op days 1, 3, 5, 7, 10, 14,
21, and 28. Eyes were observed for conjunctiva congestion,
filtering  bleb  morphology  and  sustained  time,  anterior
chamber  flare  and  hyphema,  cataract,  and  other  such
complications. Diffuse/elevated and cystic bleb was defined
as functional bleb, while flat bleb was defined as failure bleb.
Corneal endothelial cell count—A TOPCON corneal
endothelial cell count instrument (Topcon SP2000; Topcon,
Tokyo, Japan) was used to determine endothelial cell count
during  pre-op  and  day  28  post-op  according  to  the
manufactures instruction. Briefly, the head of the rabbits were
fixed in the chinrest of the machine. A confined central area
within  which  all  cells  were  marked  was  indicated.  The
integrated software of the microscope calculates the quantity
of cells. At least 3 repeated counts were performed in each
eye.
Measurement of drug concentration in aqueous humor: At
day 3, 7, 14, and 28 after filtration surgery, four rabbits in
Group  A  were  used  for  the  measurement  of  the  drug
concentration under general anesthetic. Briefly, a 1 ml syringe
was used under a ZEISS surgical microscope to biopsy 0.2 ml
of aqueous humor, and HPLC-MS was used to determine the
drug concentration in the aqueous humor.
Histologic examination: Enucleation was performed on four
randomly selected rabbits on days 7, 14, and 28 after surgery
in each group. After enucleation, the eyes were immersed in
4% paraformaldehyde for 24–28 h at 4 °C. The tissue with the
largest circumference in the filtering bleb area of the eye was
resected  and  collected.  After  paraffin  embedding,  slide
samples were collected, hematoxylin-eosin (HE) and Masson
trichrome staining were performed. HE staining was used to
observe conjunctiva epithelial integrity of the filtering bleb
area,  subconjunctival  space,  fibroblast  hypertrophy,  the
degree of infiltration of inflammatory cells in the filtering bleb
area,  retinal  involvement,  and  related  changes  [12-14].
Masson trichrome staining was used to further determine the
proliferation of new collagen fibers in the bleb region [15,
16].
Immunohistochemistry and TUNEL assay: To examine the
proliferative activity of cells adjacent to the surgical wounds,
proliferative cell nuclear antigen (PCNA) expression were
measured by immunohistochemistry. Tissues were imbedded
in paraffin, 4 μm thick sections from eyes at 28 days post-
operation were used. After deparaffinization, the tissues were
mounted on poly-L-lysine-coated slides. The sections in a
citrate buffer (0.01 mol/l, pH 6) were heated in a microwave
oven for 15 min at maximum power (700 W) and then cooled
at room temperature for 20 min. Tissues were blocked by 1%
BSA first and then incubated with PCNA primary antibody
(1:700; Millipore, Boston, MA) at room temperature for 2 h.
After washing with PBS, slides were then incubated with
biotinylated goat anti-polyvalent antibody for 15 min and then
in  streptavidin  peroxidase  for  15  min.  The  slides  were
developed for 12 min in diaminobenzidine.
For apoptotic cells analysis around the surgical wounds,
the  terminal  deoxynucleotidyl  transferasemediated  dUTP
nick end labeling (TUNEL) method was used according to the
manufacturer’s specifications (In Situ Cell Death Detection
Kit; POD; Roche Applied Sciences, Indianapolis, IN). Nuclei
were counterstained with hematoxylin.
The percentages of PCNA and TUNEL positive cells
were  calculated  by  a  computer-assisted  morphometric
analysis. Approximately 1,000 cells or nuclei were counted
for each section, 4 sections in each rabbit were analyzed.
Statistical analysis: SPSS 14.0 (SPSS Inc. Chicago, IL) was
used for statistical analysis. Numerical variables with normal
distribution are described by the mean±standard deviation
(mean±SD), non-normal distribution is described by median
and  interquartile  range,  and  categorical  variables  are
described by the number of cases (n) and its percentages.
Comparison of differing times of IOP observation within the
same group, comparison of corneal endothelial cell count pre-
op and post-op among groups with differing treatment, and
comparison of corneal endothelial cell count pre-op and post-
op within the same group is done with one-way ANOVA. If
there are significant differences in pairwise comparisons the
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2497LSD-t-test used. Comparison of filtering bleb sustained time
between groups with differing treatment is performed using
the Kaplan–Meier analysis. Test of significance is performed
by  the  log  rank  analysis.  If  p<0.05  bilaterally,  it  was
considered statistically significant.
RESULTS
Postoperative IOP changes: The average IOP among the four
groups  at  day  1  post-op  showed  a  significant  decrease
compared to pre-op, and had no statistic differences between
groups. At day 3, Groups B and D showed a rapid increase in
IOP, reaching a general equilibrium point at day 5. In Group
C, IOP began to increase at day 5, reaching pre-op levels in
10 days. While at day 28, Group A still maintained lower
average  IOP,  with  9.75±1.71  mmHg,  showing  significant
difference when compared to pre-op levels (p<0.001; Figure
2).
Clinical evaluations and complications: At day 1 post-op, all
four  groups  had  similar  average  levels  of  conjunctiva
congestion. Group A and Group C began showing slow relief
of conjunctiva congestion starting at day 3, while Group B and
Group D began showing slow relief of conjunctiva congestion
around day 5. One subject of Group C had severe corneal
edema at day 1 post-op, however it gradually receded after 3
days, with no significant corneal edema in the remaining three
groups. All four groups experienced mild anterior chamber
flare at day 1, with gradual relief around day 3. In Group C
and Group D, each had 1 case of hyphema at day 1, both
generally resolving after 5 days. There were no observable
signs of endophthalmitis, filtering bleb leakage, cataract and
other  complications  among  all  four  groups  in  28  days
observation.
Filtering bleb and survival curve: At post-op day 1, all four
groups showed diffuse filtering bleb swelling with obvious
congestion. In Group B and Group D, swelling had generally
resolved at day 3, however congestion remained, and filtering
blebs failed within 5 days post-op, with a median survival of
3 days. In Group C, swelling began to shrink and become
localized  at  day  7,  with  obvious  reduction  in  congestion,
filtering blebs failed within 10 days post-op, with a median
survival of 7 days. In Group A, swelling began to shrink and
become localized at day 7 also, but at day 14 it maintained a
stable level, and at day 28 it presents as localized bulged
filtering bleb in 6 rabbits (Figure 3 and Figure 4).
Kaplan–Meier  analysis  shows  a  significant  statistical
difference in the survival distributions between Group A and
other groups (p<0.001), and between Group C and Group B
(p<0.001), but Group B and Group D did not have statistically
significant differences (p=0.340).
Changes  in  corneal  endothelial  cell  count:  The  corneal
endothelial cell count was performed at pre-op and post-op 28
days. Table 1 showed that there were no significant changes
between groups (p>0.05), and demonstrated that there were
no  serious  side  effects  to  corneal  endothelial  cells  from
surgical  treatment  and  Sirolimus  sustained  delivery  film
application.
Sirolimus concentration in aqueous humor: At post-op days
3, 7, 14, and 28, the concentration of Sirolimus in aqueous
humor of Group A was (10.56±0.05) ng/ml, (8.62±0.05) ng/
Figure  2.  Postoperative  IOP  changes
during a 28 days period in each group.
Across all groups, IOP was at its lowest
day  1  post-op,  with  upward  trends
starting day 3. Group B and Group D had
sharp  increases  on  day  3,  surpassing
12  mmHg  on  day  5,  reaching  an
equilibrium soon after. Group C had a
slower increase, surpassing 12 mmHg
on  day  10,  and  then  reaching
equilibrium.  Group  A  continually
sustains a lower IOP than pre-op during
the observed period. #p<0.05, ※p>0.05
versus pre-op (n=4).
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2498ml, (7.74±0.05) ng/ml, and (3.77±0.05) ng/ml. Thus, we can
ascertain that the effective drug concentration in the aqueous
humor can be maintained for over two weeks.
Histological examination: Conjunctiva epithelium was intact
in  each  group  after  operation.  At  post-op  day  7,  dense
fibroblast and inflammatory cell infiltration can be seen in the
subconjunctival scleral filtration area in Group B and Group
D (Figure 5B,D), but at day 14 and day 28, there were no
infiltrate could be observed. The narrowing or disappearance
of the subconjunctival space is related directly to increase of
IOP. At post-op day 7, 14, and 28, the filtration area under the
conjunctiva and sclera showed large amounts of fibroblasts
hyperplasia and dense new collagen tissue deposition. At post-
op day 7 Group C showed a certain subconjunctival space, a
moderate number of fibroblasts hyperplasia and new collagen
deposition, the subconjunctival space disappeared by days 14
and 28, with subconjunctival and filtration area showing large
amounts of fibroblasts hyperplasia (Figure 5C,F). At post-op
day 7, 14, and 28, Group A showed clear subconjunctival
space and a small number of fibroblasts and new collagen
tissue (Figure 5A,E and Figure 6A,B). While in other groups,
subconjunctival spaces had disappeared and already formed
dense scar tissue by day 28 (Figure 6C-H). Retina and ciliary
body  remained  intact  in  all  groups,  and  no  effusion  or
detachment was observed.
PCNA and TUNEL findings: PCNA-expression was lower in
the Group A (16.25±3.24%) as compared to other groups
(B=40.75±2.75%,  C=27.75±2.36%,  D=39.75±2.22%;  n=4,
p<0.01), and it was lower in Group C than Group B and D
(p<0.01; Figure 7).
TUNEL  assay  showed  a  significant  increase  in  the
number of apoptotic fibroblasts around the surgical area in
Group  A  and  Group  C  (9.75±1.71%  and  8.50±1.92%)  as
compared  to  the  other  groups  (B=2.75±1.29%,
D=2.25±0.50%;  n=4,  p<0.01).  There  was  no  significant
difference in Group A and Group C (p>0.05; Figure 8).
The results indicated that rapamycin could inhibit the
proliferation of fibroblasts and induce its apoptosis around the
surgical region in rabbits.
Figure 3. Post-op morphological changes to filtering bleb. Group B and Group D was sustained for less than 3 days, and Group C for 14 days.
Group A filtering bleb sustained for greater than 28 days.
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2499DISCUSSION
Filtration  surgery  is  one  of  the  most  effective  treatment
methods  for  glaucoma  patient,  but  often  failed  due  to
excessive scarring. Currently, first line perioperative anti-
proliferative drugs, include MMC, 5-FU, etc, have improved
the success rate of the surgery. But the toxicity of existing
drugs and the drug delivery system are still questionable.
Usually, the surgeons placed a medication-soaked sponge pad
above and/or below the scleral flap for a certain time, and then
washed out with PBS. Because these drugs have an immense
inherent cytotoxicity, and the delivery system is not sustained,
there  is  a  great  disparity  in  drug  concentration  and
uncontrolled complications [17-21]. In addition, it had been
well established that the active proliferation of fibrosis during
incision healing of filtration surgery can last up to two weeks
after surgery [22]. Apparently, the time of MMC and 5-FU
immersion  is  deficient,  and  the  efficacy  of  the  anti-
metabolism treatment is transient, and is not ideal for long-
term  anti-proliferation  treatment.  Therefore,  finding  an
effective,  long  lasting  treatment  with  low  toxicity  is  an
important aspect of glaucoma research.
Sustained drug delivery system (DDS) is a usefully way
to get stable, effective, and long-term drug treatment effects.
Currently,  DDS  including  eye  implants,  liposomes,
biodegradable  polymers,  and  electric  pulse  directed  drug
delivery systems, etc [23-29]. Polyactic acid (PLA) and its
derivatives has been a significant progress in the field of
medical study. PLA does not accumulate in the body, has no
immunogenicity or antigenicity, and does not have side effects
on local tissue or the body at large [30-35]. The copolymer of
PLA  and  polyglycolic  acid  (PGA),  polymer
polylactioglycolic acid (PLGA) has good biocompatibility
[36]. By changing the percentage of the content in PLGA
(PLA or PGA), the time of degradation and rate of drug release
Figure 4. Survival curve of the filtering
bleb of each group (n=8). In Group B
and  Group  D,  filtering  blebs  failed
within 5 days post-op, with a median
survival  of  3  days.  Group  C  filtering
blebs failed within 10 days post-op, with
a median survival of 7 days. Group A
had 6 filtering blebs still sustained by the
end of the observation period.
TABLE 1. CORNEAL ENDOTHELIAL CELL COUNT (/MM
2, MEAN±SD) CHANGES AT PRE-OP AND POST-OPERATION AT DAY 28.
Group n pre- operation post-operation t value p value
A 8 2394.1±219.6 2353.9±129.6 0.621 0.545
B 8 2415.5±188.2 2384.3±136.9 0.379 0.711
C 8 2336.2±142.1 2287.2±119.2 0.747 0.467
D 8 2374.3±192.5 2279.8±114.8 1.191 0.253
F value   0.332 1.325    
P value   0.802 0.286    
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2500Figure 5. Histopathologic features of the surgical area in different groups. A, E: At day 7 and day 14 post-op in Group A, respectively, showing
intact conjunctiva epithelium (CE), only mild inflammation infiltrate in subconjunctiva scleral filtration area, wide conjunctiva and scleral
space (S), and small amounts of fibroblasts in Tenon’s Capsule (TC). B, E: Group B and Group D showing that conjunctival epithelium (CE)
is intact, infiltration of inflammation around the subconjunctival scleral filtration area, conjunctiva flap and sclera (S) space narrowing, and
dense fibroblasts hyperplasia in the Tenon’s Capsule (TC) at 7 days post-op. *represents sustained-release drug film area in B. C: Showing a
moderate number of fibroblasts hyperplasia and a certain subconjunctiva space at day 7 post-op In Group C, however, F, shows dense fibroblasts
hyperplasia in the Tenon’s Capsule (TC) and subconjunctival space almost disappear at day 14 post-op. (H-E staining, original magnification:
A 40×; B 200×; C 200×; D 200×; E 100×; F 100×).
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2501Figure 6. Histopathologic features of the surgical area in each group at 28 days post-op. A-H represent pathological changes in the surgical
area of Group A, Group B, Group C, and Group D at 28 days post-op, respectively. Conjunctiva Epithelium (CE) in each group are in good
condition, conjunctiva flap and scleral (S) space are wide in A and B, and the Tenon’s Capsule (TC) has few fibroblasts and new collagen
tissue. In C-H conjunctiva flap and scleral space narrow or even disappear, and a large amount of fibroblasts hyperplasia and new collagen
tissue  deposition  can  be  observed  in  the  Tenon’s  Capsule  (TC).  *represents  sustained-release  drug  film  area.  H-E  staining,  original
magnification: A 40×; C 40×; E 100×; G 100×. Masson trichrome staining, original magnification: B 40×; D 100×; F 100×; H 40×.
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2502can then be adjusted. The degradation of the PLGA surface
forms  porous  surfaces  that  constantly  deliver  its  internal
encapsulation of drugs, and thus can be used as an implantable
carrier [37-39]. In the present study, the PLGA film which
synthesis  by  PLGA50:50poly(DL-lactide-co-glycolide)
inherent viscosity 0.17 dl/g and PLGA50:50poly(DL-lactide-
co-glycolide) inherent viscosity 0.55–0.75 dl/g, was starting
to degenerated by 2 weeks, and then absorbed and degenerated
day by day until 2 months. This degeneration time make sure
the Sirolimus concentration maintain constant until the bleb
formation.
Sirolimus, a new, potent, low toxicity macrolide, has been
demonstrated that primarily inhibit the mammalian target of
rapamycin  (mTOR),  thus  interfering  with  the
phosphoinositide 3-kinase (PI3K)-Akt-mTOR axis, that is a
key  signal  pathway  to  modulate  cellular  differentiation,
viability and growth [7,40]. Some reports also stated that
Sirolimus is a potential inhibitor that blocked the proliferation
of several kinds of cells at the Gl restriction point [7-10].
Salas-Prato  et  al.  [11]  illustrated  that  Sirolimus  potently
inhibits  platelet-derived  growth  factor  (PDEF)  and  basic
fibroblast  growth  factor  (b-FGF)  induced  fibroblast
proliferation on human Tenon’s fibroblast proliferation after
Figure  7.  Proliferating  cell  nuclear
antigen (PCNA) analysis in each group
at  28  days  post-op.  A-D:
Immunohistochemistry  for  PCNA:  A:
Group A, B: Group B, C: Group C, D:
Group D. E: Quantitation of the number
of  PCNA  positive  cells  in  the
subconjunctival  space  at  post-op  28
days. *p<0.01 for treated (rapamycin)
versus control (Group B and D; n=4).
Original magnification: 200×.
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2503glaucoma filtration surgery, and was not cytotoxic at any of
the concentrations tested. These findings give us new horizon
on the anti-proliferation study on filtration surgery.
Here,  we  used  Sirolimus  applied  via  a  PLGA  drug
sustained delivery film, not only solved the Sirolimus related
problems, such as limited solubility, easy precipitation, and
instability at room temperature, but also get a stable release
of the medication, achieving an effective local concentration.
In our study, we demonstrated that the film itself had good in
vivo  biocompatibility  and  carries  no  significant  ocular
toxicity  (Group  B).  After  implantation  under  conjunctiva,
there  was  no  significant  inflammation,  tissue  necrosis,  or
other adverse reactions, and no effect on corneal endothelium
or retina. In Siromilus treated group (Group A and C), they
maintained a low IOP for a longer time comparing to no
treatment  group  (Group  D),  and  post-op  inflammatory
infiltration is mild, and no toxic effects were observed on the
tissue tested. Furthermore, the sustained Siromilus delivery
group (Group A) analysis revealed that there was a sustained
drug  release  concentration  preserved  over  2  weeks,  and
Figure 8. Apoptosis by TUNEL assay in
each  group  at  28  days  post-op.  A-D:
Immunohistochemical  analysis  for
apoptosis by TUNEL assay. A: Group
A, B: Group B, C: Group C, D: Group
D.  E:  Quantitation  of  the  number  of
apoptotic  fibroblasts  in  the
subconjunctival  space  at  post-op  28
days. *p<0.01 for treated (rapamycin)
versus control (Group B and D; n=4).
Original magnification: 200×.
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2504maintained low IOP and filtering bleb for a much longer
period  of  time,  and  had  milder  post-op  inflammation.  In
addition,  the  pathological  results  showed  that  the
subconjunctival space of Group A was wide at days 7, 14, and
28 post-op, with small amounts of fibroblasts hyperplasia and
new collagen tissue deposition, and inflammatory infiltrate
around  the  surgical  area  was  lighter.  According  to  the
histological examination of our study and other published
articles,  fibroblasts  are  most  active  in  the  first  2  weeks
following the glaucoma filtration surgery [22]. PLGA carrier
can deliver the Sirolimus to the surgery site for a period of
time  in  excess  of  2  weeks  [40],  therefore  it  meets  the
requirements  of  anti-proliferation  treatment  strategy.
Although Sirolimus delivery system showed no significant
inflammation response or toxicity in this study, the effect is
limited in terms of time.
In  addition  to  the  histology  studies  above,  we  try  to
understand the mechanisms of Sirolimus during anti-scaring
formation course. It had been proved that PCNA (proliferating
cell nuclear antigen) first expressed in mid-G1, and plays
important role of the principle of fibroblast cell proliferation
[41].  In  our  study,  PCNA-expression  was  decreased  in
Sirolimus  treated  groups,  indicated  that  the  proliferative
activity were impeded maybe through blocking cell cycle in
the G1 Phase [42]. Also, we demonstrated that Sirolimus can
induce fibroblast apoptosis (TUNEL assay) in filtration site
for the first time in rabbit model. Consequently, Sirolimus
susteained  dilivery  system  may  have  great  potential  to
significantly improve the success rate of glaucoma filtration
surgery.
In  summary,  Silolimus  sustained  delivery  film  was
proven  to  be  able  to  safely  and  effectively  inhibit
inflammation and fibroblast proliferation surgery in rabbit
eyes during glaucoma filtration surgery, preventing filtering
bleb  scarring  and  increasing  the  success  rate  of  filtration
surgery. This makes Silolimus a very promising new drug in
the field of glaucoma research.
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